Santen Pharmaceutical Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3336000009
JPY
1,579.00
-2 (-0.13%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

880.8 k

Shareholding (Mar 2025)

FII

0.03%

Held by 1 FIIs

DII

99.97%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 6.50%

  • The company has been able to generate a Return on Equity (avg) of 6.50% signifying low profitability per unit of shareholders funds
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 20.92

 
3

Poor long term growth as Operating profit has grown by an annual rate 4.56% of over the last 5 years

 
4

Flat results in Jun 25

5

With ROE of 12.52%, it has a very attractive valuation with a 1.95 Price to Book Value

6

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JPY 560,128 Million (Mid Cap)

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.03%

stock-summary
Debt Equity

-0.18

stock-summary
Return on Equity

11.06%

stock-summary
Price to Book

1.99

Revenue and Profits:
Net Sales:
68,737 Million
(Quarterly Results - Jun 2025)
Net Profit:
5,863 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.1%
0%
-4.1%
6 Months
-4.94%
0%
-4.94%
1 Year
-7.55%
0%
-7.55%
2 Years
13.35%
0%
13.35%
3 Years
39.0%
0%
39.0%
4 Years
11.83%
0%
11.83%
5 Years
-7.55%
0%
-7.55%

Santen Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.43%
EBIT Growth (5y)
4.56%
EBIT to Interest (avg)
20.92
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.32
Sales to Capital Employed (avg)
0.91
Tax Ratio
24.14%
Dividend Payout Ratio
34.62%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
16.84%
ROE (avg)
6.50%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
1.95
EV to EBIT
9.29
EV to EBITDA
6.84
EV to Capital Employed
2.41
EV to Sales
1.55
PEG Ratio
0.38
Dividend Yield
0.03%
ROCE (Latest)
25.95%
ROE (Latest)
12.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -8.07% vs 3.29% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -44.73% vs 1.91% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "68,737.00",
          "val2": "74,771.00",
          "chgp": "-8.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12,028.00",
          "val2": "18,157.00",
          "chgp": "-33.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "749.00",
          "val2": "407.00",
          "chgp": "84.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5,863.00",
          "val2": "10,607.00",
          "chgp": "-44.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "109.60%",
          "val2": "179.90%",
          "chgp": "-7.03%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -0.65% vs 8.22% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 34.27% vs 278.09% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "300,004.00",
          "val2": "301,965.00",
          "chgp": "-0.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "74,179.00",
          "val2": "70,081.00",
          "chgp": "5.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1,083.00",
          "val2": "831.00",
          "chgp": "30.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10,140.00",
          "val2": "-15,718.00",
          "chgp": "35.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "35,844.00",
          "val2": "26,695.00",
          "chgp": "34.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "187.40%",
          "val2": "171.90%",
          "chgp": "1.55%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
68,737.00
74,771.00
-8.07%
Operating Profit (PBDIT) excl Other Income
12,028.00
18,157.00
-33.76%
Interest
749.00
407.00
84.03%
Exceptional Items
0.00
0.00
Consolidate Net Profit
5,863.00
10,607.00
-44.73%
Operating Profit Margin (Excl OI)
109.60%
179.90%
-7.03%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -8.07% vs 3.29% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -44.73% vs 1.91% in Jun 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
300,004.00
301,965.00
-0.65%
Operating Profit (PBDIT) excl Other Income
74,179.00
70,081.00
5.85%
Interest
1,083.00
831.00
30.32%
Exceptional Items
-10,140.00
-15,718.00
35.49%
Consolidate Net Profit
35,844.00
26,695.00
34.27%
Operating Profit Margin (Excl OI)
187.40%
171.90%
1.55%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -0.65% vs 8.22% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 34.27% vs 278.09% in Mar 2024

stock-summaryCompany CV
About Santen Pharmaceutical Co., Ltd. stock-summary
stock-summary
Santen Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available